Allergan will be acquired by AbbVie for approximately $63 billion in cash and stock, the two companies announced in a press release.
Under a definitive transaction agreement, which has been signed by both entities, Allergan shareholders will receive 0.8660 AbbVie shares and $120.30 in cash for each Allergan share they hold.
"This acquisition creates compelling value for Allergan's stakeholders, including our customers, patients and shareholders. With 2019 annual combined revenue of approximately $48 billion, scale in more than 175 countries, an industry-leading R&D pipeline and robust cash
Uncategorized